Company intelligence / Profile preview
Armaron Bio
Melbourne, Victoria, Australiarocketreach.co ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Developing NP202, a flavonol-based small molecule showing anti-fibrotic effects in cardiac remodeling. Phase1 demonstrated safety up to1600mg single dose and1000mg/day for14 days. Phase2 trials focus on left ventricular dysfunction post-MI and atrial fibrillation prevention.
- Therapeutic areas
- NephrologyNeurologyCardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
MedImmune VenturesStarfish VenturesJohn Hunter Hospital
Beyond the preview
Go deeper on Armaron Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Armaron Bio.